Abstract
After the first patent laws on inventions were enacted in the late eighteenth century, parliaments, governments, institutions, and medical professions endeavored to limit or suspend the extension of monopolies on remedies, in the interests of public health. In 1844 the French parliament, against the government’s advice, prohibited patents on medicines for a century. In this respect it followed the line of the Académie de Médecine, which at the time was fiercely opposed to monopolies on medicinal remedies. After 1944, when pharmaceutical processes could again be patented in France, the government instituted a “special license” justified in the name of public health. This measure granted the Ministry of Health the authority to resort to such a license if it deemed that medicines were not sufficiently accessible in terms of price, quality, or quantity (Cassier, 2000). Despite the early internationalization of patent rights, via the Paris Convention of 1883, many other states also excluded medicines from patenting. This was the case for instance in West Germany, until 1968, and Japan, until 1975. The developing countries of interest to us here, Brazil and India, likewise opted for the nonpatentability of pharmaceutical products, respectively, in 1945 and 1970. In 1994 a new phase of globalization of intellectual property (IP) was, however, initiated with WTO trade regulations that extended 20-year patents on medicines to all member countries (May, 2000).
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Bibliography
ABIA (2009) “IPR and access to ARV medicines: Civil society resistance in the Global South,” report, 135 pages.
Barroso W (2009) “ Le cas du Tenofovir,” communication au 5ème Congrès VIH/sida de Casablanca, Mars 2010.
Basso M (2006) “Intervention of health authorities in patent examination: The Brazilian practice of the prior consent,” International Journal of Intellectual Property Management, 1, 1/2, 54–74.
Beigbeder Yves (2004), International Public Health: Patients’ Rights Vs. Patent Rights, Ashgate.
Biehl J (2009) “Accès au traitement du sida, marchés des médicaments et citoyenneté dans le Brésil d’aujourd’hui, Sciences Sociales et Santé”, Sciences Sociales et santé, 3, 27, 13–46.
Cassier M (2000) “Genome patents nowadays and pharmaceutical patents in the 19th: A parallel,” International Conference, “Technological Policy and Innovation: Economic and historical perspectives,” Paris, November 20–22, 22 pages.
Cassier M (2002) “Propriété intellectuelle et santé publique”, Revue Projet, Mai, p. 47–55.
Cassier M, Correa M (2003) “Patents, innovation and public health: Brazilian public-sector laboratories’ experience in copying aids medicines,” in Economics of AIDS and Access to HIV/AIDS Care in Developing Countries. Issues and Challenge, Ed. ANRS, pp. 89–107.
Cassier M, Stoppa Lyonnet D (2005) “L’opposition contre les brevets de Myriad Genetics et leur révocation totale ou partielle en Europe” [Opposition to Myriad Genetics patents and their total or partial revocation in Europe: Early conclusions], Médecine/Sciences, 6–7, 21, June–July, 658–62.
Chaves G, Viera M, Reis R (2008) “Access to medicines and intellectual property in Brazil: Reflections and strategies of civil society”, Sur Revista Internatcional de Direitos Humanos, 5, 8, June.
Cohen J C (2000) “Public choices in the pharmaceutical sector: a case study of brazil”. LCHSD Paper Series n° 54, Human development Department, The World Bank.
Commission on Intellectual Property Rights — CIPR (2002) Integrating Property Rights and Development Policy, 178 pages.
Correa Carlos (2007) Guidelines for the examination of pharmaceutical patents: Developing a public health perspective. ICTSD, WHO, UNCTAD, 2007.
D’Almeida C, et al. (2008) “New antiretroviral treatments and post-2005 TRIPS constraints: First moves towards IP flexibilization in developing countries” in Political Economy of HIV/AIDS in Developing Countries, ed. B. Coriat, Edward Elgar, London, 25–51.
Ecks Stefan (2008) “Global pharmaceutical markets and corporate citizenship: The case of Novartis’ anti-cancer medicine Glivec,” Biosocieties 3, 165–81.
Foucault M (2004) Naissance de la biopolitique, Cours au collège de France (1978–1979), Seuil.
Flynn M, 2007, “Brazil’s use of compulsory licenses for AIDS medicines,” American Sociological Association, August 1–4, 1–20.
Flynn M, De Oliviera E A (2009) “Regulatory capitalism in emerging markets: An institutional analysis of Brazil’s Health Surveillance Agency (ANVISA),” American Sociological Association, August 8–11, San Francisco, 1–20.
Galvao J. (2002) “Access to antiretroviral medicines in Brazil,” Lancet, 360, 9348, 1862–65.
Guimaraes E (2008) “Le droit à la santé et la propriété intellectuelle des médicaments au Brésil: l’examen préalable à l´Agence de Surveillance Sanitaire” mémoire de Mestrado, Institut de Médecine Sociale, UERJ.
Harhoff D (2000) “Determinants of opposition against EPO patent grants: The case of biotechnology and pharmaceuticals”, collection Les Cahiers de l’innovation, CNRS, 27 pp.
Lanjouwe J.O. (1997) “The introduction of pharmaceutical products patents in India: Heartless exploitation of the poor and suffering?”, Yale University, 54 pages.
Latour B (2002) La Fabrique du droit, La Découverte.
Loyola MA. (2009) “Sida, santé publique et politique du médicament au Brésil: autonomie ou dependence,” Sciences Sociales et santé, 3, 27, pp. 47–75.
National Academy of Science (1997) “America’s vital interest in global health: Protecting our people, enhancing our economy and advancing our international interest”, Board on International Health, Institute of Medicine, National Academy Press, Washington, DC.
May C (2000) a Global Political Economy of Intellectual Property Rights: The New Enclosures?, Routledge.
Possas C (2008) “Compulsory licensing in the real world: The case of arv medicines in Brazil,” in The Political Economy of HIV/AIDS in Developing Countries, ed. B. Coriat, Edward Elgar, London, 150–66.
Sahu S (1998) “Technology transfer, dependence, and self-reliant development in the third world,” Praeger, 250 p.
Shanker D. (2001) “Brazil, Pharmaceutical Industry and WTO,” University of Wollongong, New South Wales, Australia.
Scherer F (2000) “Le système des brevets et l’innovation dans le domaine pharmaceutique,” Revue Internationale de Droit Economique, n°1.
Scherer F and Watal J (2001) “Post trips options for access to patented medicines in developing countries,” Commission on Macroeconomics and Health, WHO, 2001, 77 pages.
Shelden K (2009) “The political contradictions of incremental innovation in late development: Lessons from pharmaceutical patent examination in Brazil,” 1–29.
Tahir Amin (2008) “Making the patent system more democratic: The role or public participation,” Examination of Pharmaceutical Patents: Arguing from a Pro-Public Health Perspective, Associacao Brasileira Interdisciplinar de AIDS — ABIA Rio de Janeiro, November 18.
Teixeira P, Vitoria MC, Barcarolo (2003) “The Brazilian experience in providing universal access to antiretroviral therapy,” in Moatti J.-P., Coriat B., Souteyrand Y., Barnett T., Dumoulin J., Flori Y.-A., eds, Economics of AIDS and access to HIV/AIDS: Issues and Challenge, ed. ANRS.
Varella M (2002) La propriété intellectuelle des produits pharmaceutiques au Brésil, 66 pages.
Velasquez G, Correa C, Thirukumaran Balasubramaniam (2004) “who in the frontlines of the access to medicines battle: The debate on intellectual property rights and public health,” Intellectual Property in the context of the WTO TRIPS Agreement, ed. J. Bermudez, MA Oliviera, Fiocruz, 83–97.
Villela Pedro (2009) “Activistes du VIH/SIDA et l’économie politique du médicament,” Master’s thesis, EHESS, Paris.
Editor information
Editors and Affiliations
Copyright information
© 2013 Maurice Cassier
About this chapter
Cite this chapter
Cassier, M. (2013). Pharmaceutical Patent Law In-the-Making: Opposition and Legal Action by States, Citizens, and Generics Laboratories in Brazil and India. In: Gaudillière, JP., Hess, V. (eds) Ways of Regulating Drugs in the 19th and 20th Centuries. Science, Technology and Medicine in Modern History. Palgrave Macmillan, London. https://doi.org/10.1057/9781137291523_13
Download citation
DOI: https://doi.org/10.1057/9781137291523_13
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-33742-2
Online ISBN: 978-1-137-29152-3
eBook Packages: Palgrave History CollectionHistory (R0)